Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed) | PAR 27 069

Opportunity Information: Apply for PAR 27 069

The National Institutes of Health (NIH) funding opportunity PAR-27-069, titled "Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)," is designed to expand what researchers can learn from the All of Us Research Program by enabling access to stored participant biospecimens held in the All of Us Biobank. Specifically, the announcement invites applications to use existing stored blood plasma, blood serum, and extracted DNA to run new assays and generate new molecular data. The overall goal aligns with the All of Us mission: to speed up health research and medical breakthroughs that support individualized prevention, treatment, and care across diverse populations.

A central feature of this opportunity is that it supports "partnered research studies." In practice, these are collaborative projects sponsored and funded by an entity external to the All of Us Research Program, with the intent to collect or generate new data and then return those data to the All of Us Researcher Workbench for broad use by the wider scientific community. The X01 mechanism is the required entry point under this announcement for investigators who want to carry out these partnered studies using All of Us biospecimens. The idea is not only to allow one-off analyses, but also to strengthen the overall dataset in a way that benefits future investigators, creating a compounding effect where each approved project can add value for many downstream studies.

The scientific emphasis is on biospecimen-based analyses that can be integrated with the rich set of existing All of Us data, including clinical information, environmental factors, and life-course data. By leveraging stored plasma, serum, and DNA, researchers can generate multi-omics profiles such as genomics, proteomics, metabolomics, and other high-dimensional molecular measurements. This matters because combining molecular signals with longitudinal health records and participant-reported information can support more powerful discovery, improve disease prediction, and help identify subtypes of disease that might respond differently to prevention strategies or treatments. The announcement also highlights the longer-term infrastructure benefit: projects can contribute to longitudinal follow-up and repeat sampling approaches and help build pathways that support future clinical trial recruitment, along with enabling public-private partnership models that accelerate translation.

NIH identifies several high-priority research directions that are particularly responsive to this announcement. These include large-scale integrated multi-omics efforts, early disease detection approaches, biomarker discovery or biomarker validation studies, creation of new risk models that predict incident (new-onset) disease, and novel methods of disease stratification that improve chronic disease risk assessment, diagnosis, and prognosis. The common thread across these areas is an emphasis on precision medicine: using data-driven biological and clinical insights to better tailor prevention and care to individuals and subgroups, rather than relying on one-size-fits-all averages.

From an administrative and eligibility standpoint, the opportunity is broad and open to many applicant types. Eligible applicants include various levels of government (state, county, city/township, and special district), eligible tribal governments and tribal organizations, public housing authorities/Indian housing authorities, independent school districts, public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), and for-profit organizations (including small businesses and other for-profits that are not small businesses). Importantly, the announcement explicitly allows foreign participation: non-U.S. entities may apply, non-U.S. components of U.S. organizations are eligible, and foreign components are permitted as defined in the NIH Grants Policy Statement. This structure reflects an intent to attract strong projects from across the global research community, as long as the work fits the partnered research model and contributes back to the All of Us resource.

The funding instrument is listed as "Other," and the activity is categorized under Health (CFDA 93.368). The closing date provided is March 1, 2027. The notice also makes clear that clinical trials are not allowed under this opportunity, which means applications should be focused on biospecimen analysis and related observational or methodological research activities rather than interventional studies that assign participants to treatments. For practical planning details, NIH points applicants to the All of Us X01 Partnered Research Studies Resource webpage and instructs applicants to consult the NOFO's eligibility section for additional requirements and conditions tied to the use of All of Us biospecimens and the expectation that newly generated data are added back to the Researcher Workbench for broad community benefit.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.368.
• This funding opportunity was created on 2026-05-19.
• Applicants must submit their applications by 2027-03-01.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 27 069

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: